Spinal muscular atrophy is a rare, genetic disease that causes severe muscle atrophy and weakness in infants and children. Ongoing mid-stage studies are showing that the drug increases muscle function in those suffering from the disease.
Isis currently enrolling infants with the disease in a phase 3 study, and it plans to begin a second phase 3 study of children with SMA later this year, according to the report.
More articles on devices:
37 spine, orthopedic devices receive FDA 510(k) clearance in September
Nevro files IPO — 6 things to know
BD buys CareFusion for $12.2B: 8 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
